PMID- 29192956
OWN - NLM
STAT- MEDLINE
DCOM- 20181211
LR  - 20211204
IS  - 1897-4279 (Electronic)
IS  - 0022-9032 (Linking)
VI  - 76
IP  - 2
DP  - 2018
TI  - Initial clinical experience with the first drug (sacubitril/valsartan) in a new 
      class - angiotensin receptor neprilysin inhibitors in patients with heart failure 
      with reduced left ventricular ejection fraction in Poland.
PG  - 381-387
LID - 10.5603/KP.a2017.0230 [doi]
AB  - BACKGROUND: Sacubitril/valsartan is the first drug from a new class of 
      angiotensin receptor neprilysin inhibitors (ARNIs) recommended in the new 
      European Society of Cardiology guidelines instead of angiotensin converting 
      enzyme inhibitors (ACEI), or angiotensin receptor blockers (ARB) that are used if 
      ACEI are not tolerated. Sacubitril/valsartan is recommended for further reduction 
      in the risk of hospitalisation or death in outpatients with heart failure with 
      reduced ejection fraction (HFrEF) if symptoms continue despite optimal treatment 
      with ACEI/ARB, beta-blockers, and mineralocorticoid antagonists. AIM: The aim of 
      this study is to present the initial experience with regard to the effectiveness, 
      tolerance, and safety of sacubitril/valsartan in the outpatient cardiology 
      practice in Poland. METHODS: The study is a retrospective analysis of data 
      obtained through a questionnaire filled in by the physicians who initiated the 
      sacubitril/valsartan treatment in patients with HFrEF between 1 June 2016 and 30 
      September 2016. Patients were followed-up for three months. RESULTS: The analysis 
      included data on 28 patients aged 61 +/- 16 years, of whom 85.7% were males. The 
      drug was used in patients in New York Heart Association (NYHA) class I-III. In 25 
      (89.2%) patients sacubitril/valsartan was started at the lowest dose (24/26 mg 
      BID). During follow-up the sacubitril/valsartan-treated patients had a reduction 
      in HF symptoms assessed using the NYHA functional class (p = 0.001), a 
      significant drop in N-terminal-pro B-type natriuretic peptide levels (mean, from 
      2900 to 2270 pg/mL; p = 0.008), and improved exercise tolerance, which occurred 
      shortly after treatment initiation - after a mean of 28 days. CONCLUSIONS: It was 
      demonstrated that the use of sacubitril/valsartan in outpatients with HFrEF is 
      safe and is associated with a significant clinical improvement.
FAU - Kaluzna-Oleksy, Marta
AU  - Kaluzna-Oleksy M
AD  - 1st Department of Cardiology, University of Medical Sciences, Poznan, Poland. 
      marta.kaluzna@wp.pl.
FAU - Kolasa, Jolanta
AU  - Kolasa J
FAU - Migaj, Jacek
AU  - Migaj J
FAU - Pawlak, Agnieszka
AU  - Pawlak A
FAU - Lelonek, Malgorzata
AU  - Lelonek M
FAU - Nessler, Jadwiga
AU  - Nessler J
FAU - Straburzynska-Migaj, Ewa
AU  - Straburzynska-Migaj E
LA  - eng
PT  - Journal Article
DEP - 20171201
PL  - Poland
TA  - Kardiol Pol
JT  - Kardiologia polska
JID - 0376352
RN  - 0 (Aminobutyrates)
RN  - 0 (Angiotensin Receptor Antagonists)
RN  - 0 (Biphenyl Compounds)
RN  - 0 (Drug Combinations)
RN  - 0 (Peptide Fragments)
RN  - 0 (Tetrazoles)
RN  - 0 (pro-brain natriuretic peptide (1-76))
RN  - 114471-18-0 (Natriuretic Peptide, Brain)
RN  - 80M03YXJ7I (Valsartan)
RN  - WB8FT61183 (sacubitril and valsartan sodium hydrate drug combination)
SB  - IM
MH  - Aged
MH  - Aminobutyrates/adverse effects/*therapeutic use
MH  - Angiotensin Receptor Antagonists/adverse effects/*therapeutic use
MH  - Biphenyl Compounds
MH  - Drug Combinations
MH  - Female
MH  - Heart Failure/blood/*drug therapy/physiopathology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Natriuretic Peptide, Brain/blood
MH  - Outpatients
MH  - Patient Safety
MH  - Peptide Fragments/blood
MH  - Poland
MH  - Retrospective Studies
MH  - *Stroke Volume
MH  - Tetrazoles/adverse effects/*therapeutic use
MH  - Treatment Outcome
MH  - Valsartan
MH  - Ventricular Dysfunction, Left
OTO - NOTNLM
OT  - ARNI
OT  - heart failure with reduced ejection fraction
OT  - sacubitril/valsartan
EDAT- 2017/12/02 06:00
MHDA- 2018/12/12 06:00
CRDT- 2017/12/02 06:00
PHST- 2017/08/04 00:00 [received]
PHST- 2017/10/26 00:00 [accepted]
PHST- 2017/09/28 00:00 [revised]
PHST- 2017/12/02 06:00 [pubmed]
PHST- 2018/12/12 06:00 [medline]
PHST- 2017/12/02 06:00 [entrez]
AID - VM/OJS/KP/11553 [pii]
AID - 10.5603/KP.a2017.0230 [doi]
PST - ppublish
SO  - Kardiol Pol. 2018;76(2):381-387. doi: 10.5603/KP.a2017.0230. Epub 2017 Dec 1.